Yi Eunjue, Chang Ji-Eun, Leem Chosun, Jeon Chang-Ho, Jheon Sanghoon
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.
Respiratory Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.
J Cancer. 2017 May 12;8(8):1324-1329. doi: 10.7150/jca.18086. eCollection 2017.
The melanoma-associated antigen (MAGE) genes are known to be expressed in various kinds of tumors including lung cancer. Although they are studied as targets for immunotherapy and tools for early detection of lung cancer, the correlation between MAGE expression and the prognosis in lung cancer has not been clarified. In this study, we evaluated the relationship between MAGE A1-6 gene expression and the clinical prognosis in lung cancer. Bone marrow aspirations were performed in 60 patients who were diagnosed as lung cancer and underwent lung cancer surgery between 2007 and 2008. Each bone marrow was examined using nested reverse transcription- polymerase chain reaction (RT-PCR) with the MAGE common primer to detect MAGE A1-6. Overall survival rate, disease-free survival rate, recurrence, and distant metastasis were reviewed retrospectively. Survival periods were analyzed using SPSS ver. 20.0. Of the total 60 lung cancer patients, 9 patients (15%) had MAGE A1-6. MAGE A1-6-positive patients showed poor overall survival and overall disease-free survival rates (43.8 ± 26.1, 43.2 ± 26.9 months, respectively) compared with MAGE A1-6-negative patients (54.4 ± 17.2, 44.8 ± 22.1 months, respectively). No significant difference was shown in either survival rates. In conclusion, MAGE A1-6 expression of bone marrow in lung cancer patients correlated with poor survival rates. We suggest that MAGE A1-6 may be considered as a novel prognostic factor for lung cancer which leads to effective follow-up and treatment.
黑色素瘤相关抗原（MAGE）基因在包括肺癌在内的各种肿瘤中均有表达。尽管它们作为免疫治疗的靶点和肺癌早期检测的工具被研究，但MAGE表达与肺癌预后之间的相关性尚未明确。在本研究中，我们评估了MAGE A1 - 6基因表达与肺癌临床预后之间的关系。对2007年至2008年间被诊断为肺癌并接受肺癌手术的60例患者进行了骨髓穿刺。使用MAGE通用引物通过巢式逆转录 - 聚合酶链反应（RT-PCR）检测每个骨髓中的MAGE A1 - 6。回顾性分析总生存率、无病生存率、复发和远处转移情况。使用SPSS 20.0版分析生存期。在60例肺癌患者中，9例（15%）有MAGE A1 - 6表达。与MAGE A1 - 6阴性患者（分别为54.4±17.2、44.8±22.1个月）相比，MAGE A1 - 6阳性患者的总生存率和总无病生存率较差（分别为43.8±26.1、43.2±26.9个月）。两种生存率均未显示出显著差异。总之，肺癌患者骨髓中的MAGE A1 - 6表达与较差的生存率相关。我们建议MAGE A1 - 6可被视为肺癌的一种新的预后因素，这有助于进行有效的随访和治疗。
